Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Partitioning of TSE infectivity during ethanol fractionation of human plasma.

Gregori L, Maring JA, MacAuley C, Dunston B, Rentsch M, Kempf C, Rohwer RG.

Biologicals. 2004 Mar;32(1):1-10.

PMID:
15026020
2.

Impacts and concerns for vCJD in blood transfusion: current status.

MacGregor IR, Prowse CV.

Curr Mol Med. 2004 Jun;4(4):361-73. Review.

PMID:
15354867
3.

A 25 nm virion is the likely cause of transmissible spongiform encephalopathies.

Manuelidis L.

J Cell Biochem. 2007 Mar 1;100(4):897-915. Review.

PMID:
17044041
4.

Prion diseases and emerging prion diseases.

Yokoyama T, Mohri S.

Curr Med Chem. 2008;15(9):912-6. Review.

PMID:
18473798
5.

[Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Part II].

Zaborowski A.

Psychiatr Pol. 2004 Mar-Apr;38(2):297-309. Review. Polish.

PMID:
15307294
7.

Molecular aspects of disease pathogenesis in the transmissible spongiform encephalopathies.

Priola SA, Vorberg I.

Methods Mol Biol. 2004;268:517-40. Review.

PMID:
15156065
8.

Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products.

Ironside JW, Head MW.

Haemophilia. 2004 Oct;10 Suppl 4:64-9. Review.

PMID:
15479374
9.

The use of non-prion biomarkers for the diagnosis of Transmissible Spongiform Encephalopathies in the live animal.

Parveen I, Moorby J, Allison G, Jackman R.

Vet Res. 2005 Sep-Dec;36(5-6):665-83. Review.

10.

Leucodepletion for transmissible spongiform encephalopathies.

St Romaine C, Hazlehurst G, Jewell AP.

Br J Biomed Sci. 2004;61(1):48-54. Review.

PMID:
15058746
11.

Atypical transmissible spongiform encephalopathies (TSEs) in ruminants.

Baron T, Biacabe AG, Arsac JN, Benestad S, Groschup MH.

Vaccine. 2007 Jul 26;25(30):5625-30. Epub 2006 Nov 13. Review.

PMID:
17126958
12.

Pathogenesis and transfusion risk of transmissible spongiform encephalopathies.

Brown P.

Dev Biol (Basel). 2005;120:27-33. Review.

PMID:
16050152
13.

Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.

Soluk L, Price H, Sinclair C, Atalla-Mikhail D, Genereux M.

Am J Ther. 2008 Sep-Oct;15(5):435-43. doi: 10.1097/MJT.0b013e318160c1b7. Review.

PMID:
18806519
14.

Consensus statement on the bio-safety of urinary-derived gonadotrophins with respect to Creutzfeldt-Jakob disease.

Balen AH, Lumholtz IB.

Hum Reprod. 2005 Nov;20(11):2994-9. Epub 2005 Jul 29.

PMID:
16055457
15.
17.
18.

Tissue safety in view of CJD and variant CJD.

Pauli G.

Cell Tissue Bank. 2005;6(3):191-200. Review.

PMID:
16151959
19.

The tubulovesicular structures - the ultrastructural hallmark for all prion diseases.

Liberski P.

Acta Neurobiol Exp (Wars). 2008;68(1):113-21. Review.

20.

Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE Bayer.

Lee DC, Miller JL, Petteway SR Jr.

Haemophilia. 2002 Mar;8 Suppl 2:6-9. Review.

PMID:
11966845

Supplemental Content

Support Center